Pridopidine: Phase II started

Teva began the double-blind, placebo-controlled, international Phase II PRIDE-HD trial to evaluate 45, 67.5, 90 and 112.5 mg oral pridopidine twice daily for 26 weeks in about 400 patients ages >=21 y...